The undecapeptide substance P is thought to mediate both vasodilatation and augmented vascular permeability when released from sensory nerve endings in the skin. Substance P also induces mast cell degranulation in vitro or in vivo. However, the extent to which substance P-induced changes in vascular permeability are mast cell-dependent is unclear. We investigated this issue by injecting substance P and certain related peptides (substance P,I4, substance P4.11) into the skin of genetically mast cell-deficient WBB6F,-W/W' or WCB6F1-SI/Sid mice, the congenic normal (+/+) mice, and WIW' mice which had undergone selective local repair of their mast cell deficiency by intradermal injection of IL-3-dependent mast cells generated in vitro from the bone marrow cells of the congenic +/+ mice. Substance P induced significant augmentation of vascular permeability and significant cutaneous swelling when injected into normal mice at doses as low as 2 pmol i.d. Substance P also induced granulocyte infiltration, although the infiltrates were modest and were seen at doses of peptide from 5 to more than 20-fold higher than those required for induction of tissue swelling. The effects of substance P on tissue swelling, vascular permeability, and granulocyte infiltration were virtually entirely mast cell dependent. By contrast, substance P-4 was inactive in our assays at 25 nmol/site, and substance P4.11 induced modest augmentation of vascular permeability, which was at least in part mast cell independent.
Introduction
The extent to which mast cells participate in neuropeptide-dependent vascular changes is the subject ofconsiderable current interest and some controversy. Several findings suggest that mast cells may importantly contribute to such processes. Kieman demonstrated that antidromic electrical stimulation (ES)' of sensory nerves induces cutaneous vasodilation and augmented vascular permeability, and also results in degranulation of cutaneous mast cells (1, 2) . Several different neuropeptides which can induce alterations in vascular tone and/or permeability when injected in vivo can also stimulate degranulation of a variety ofhuman and rodent mast cell populations in vitro or in vivo (reviewed in [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Cutaneous mast cells are particularly sensitive to stimulation by substance P (4, 5-8, 10-12, 15, 16) , which can induce a wheal and flare response when injected into the skin in doses as low as 10 pmol (4) (5) (6) (7) (8) 11) . Some neuropeptide-induced vascular changes, e.g., the flare observed immediately after injection of substance P, are markedly attenuated by administration of antihistamines (4, 8-1 1) , suggesting that such effects may be mediated by neuropeptide-dependent mast cell degranulation. Finally, morphological studies have documented a very close anatomical association between mast cells and nonmyelinated nerves (17, 18) , which in some studies have been shown to contain substance P and/or other neuropeptides (19, 20) .
Taken together, such evidence implicates mast cells as potentially important intermediaries between neuropeptide release and local alterations in vascular tone or permeability and other manifestations of inflammation. However, additional observations indicate that certain manifestations of neurogenic inflammation may occur independently of the mast cell. Investigation of the effects of H, antihistamines on the expression of substance P-induced vascular changes in human skin indicate that while the flare response is largely histamine-mediated, the more prolonged wheal component of the reaction occurs through a combination of histamine-dependent and histamine-independent mechanisms (reviewed in 8, 1 1). And while some studies indicate that neurogenically stimulated augmentation of vascular permeability can be blocked partially by H, and H2 receptor antagonists or by depletion of cutaneous mast cells (21, 22) , other studies have not demonstrated a protective effect of antihistamines in similar systems (23) (24) (25) .
Kowalski and Kaliner directly investigated the participation of mast cells in the cutaneous vascular changes induced by ES and demonstrated that while prolonged ES did cause degranulation of cutaneous mast cells, this response was detectable histologically only after significant augmentation of vascular permeability had already occurred (13) . They also showed that disodium cromoglycate (DSCG), an inhibitor of mast cell degranulation, was not able to interfere with the augmentation in cutaneous vascular permeability induced by ES, and demonstrated that genetically mast cell-deficient WBB6F1-W/W' mice and the congenic normal mice (WBB6F,-+/+ mice) exhibited no differences in the magnitude of vascular permeability responses to either ES or intravenous administration of substance P.2 The latter observation is in accord with studies showing that substance P injected intraarterially or intravenously has a rapid vasodilatory effect on human skin that is not blocked by an antihistamine (promethazine), atropine, or adrenergic blocking agents (26) . In aggregate, this evidence suggests that at least certain aspects of neurogenic or substance P-induced alterations in vascular function, and in particular augmented vascular permeability, may occur by mast cell-independent mechanisms.
To investigate directly the role of mast cells in substance P-induced alterations of vascular permeability, we injected substance P directly into the skin of genetically mast cell-deficient WBB6F1-W/WR or WCB6F,_Sl/Sld mice, the congenic normal (+/+) mice, and W/W1 mice that had undergone selective local repair of their cutaneous mast cell deficiency by adoptive intracutaneous transfer of growth factor-dependent mast cells generated in vitro from bone marrow cells derived from the congenic +/+ mice. In accord with the results of Matsuda et al. (27) , who demonstrated that substance P-induced granulocyte infiltration into subcutaneous air pouches in the mouse was largely mast cell dependent, we found that virtually all ofthe leukocyte infiltration following i.d. injection of substance P was dependent on mast cells. However, we found that substance P induced significant augmentation of cutaneous vascular permeability and tissue swelling when injected intradermally in doses as low as 2 pmol, amounts that induced no significant infiltration of leukocytes. Virtually all of the tissue swelling induced by intradermal injection of substance P was mast cell dependent.
Methods
Mice. Mast cell-deficient mice and the normal (+/+) littermates ((WB/ReJ-W/+ X C57BL/6J-W'/+)F1 -(W/W', +/+), designated here WBB6F,-W/Wv, +/+), and (WC/ReJ-Sl/+ X C57BL/6J-Sld/ +)F, -Si/Sid, +/+), designated here WCB6F1-(Sl/Sld, +/+) were purchased from the Jackson Laboratory (Bar Harbor, ME). The skin of adult WBB6F,-W/W' or WCB6F,-Sl/Sld mice contains < 1.0% the number of mast cells present in the skin ofthe congenic normal (+/+) mice (28) (29) (30) . All mice were males and were used at 4-7 mo of age unless stated otherwise.
Elicitation and analysis oftissue swelling induced by substance P. Native substance P (substance P, ,,), substance P,J, and substance P41I,, purchased from Peninsula Laboratories, Inc. (Belmont, CA) were either solubilized in vehicle immediately before injection or were made up as stock solutions, frozen at -70°C, then thawed within 2 wk, diluted, and used immediately. Peptides were solubilized either in Hanks' minimal essential medium (HMEM; Gibco Laboratories, Grand Island, NY) containing 0.47 g/liter piperazine-N,N'-bis [2- (32, 33) tissues consisted of a mixture of fibrinogen, fibrin, and fibrinogen-fibrin degradation products. Fibrinogen, fibrin monomers, and solubilized fibrin degradation products appeared in the aqueous extract; fibrin polymers not cross-linked by Factor XIII appeared in the "urea soluble" GPF extract; and cross-linked fibrin as well as some early degradation fragments of cross-linked fibrin appeared in the "urea insoluble" residue.
Assessment of substance P-induced mast cell degranulation and granulocyte infiltration. In all experiments, samples ofpeptide-injected and control (vehicle-injected) ears were obtained after sacrifice and processed for I-Mm Epon-embedded, Giemsa-stained sections (35, 36) . The sections were examined by an observer not aware ofthe identity of the individual specimens. The number of dermal mast cells per square millimeter of dermis was determined (37) and the cells were classified (at X1,000) as extensively degranulated (> 50% of the cytoplasmic granules exhibiting fusion, staining alterations, and extrusion from the cell), slightly to moderated degranulated (10-50% of the granules exhibiting fusion or discharge), or normal (37, 38) . We also quantitated the number of granulocytes present near the injection site, and expressed the results as granulocytes/mm2 of dermis, as previously de- scribed (37 (Fig. 1) . By contrast, no significant responses were detected in WBB6F,-W/Wl mice ( Fig. 1) . Because the swelling reactions were largely dissipated by 4 h after injection, most of the subsequent studies were terminated at this interval.
We next tested WCB6F1-+/+ (normal) and WCB6F,-Sl/ 4h 8h 24h Sld mice, whose mast cell deficiency is the result of a mecha-,,ce) -----nism distinct from that of W/W' mice (28) (29) (30) changes in ear thickness (32) . We therefore used this assay to hickness evaluate 2-h reactions to injection of substance P in W/W' and 1-deficient congenic normal mice. The ear swelling responses in these Jlenged in the mice were similar to those shown in Fig. 1 (Table I) . Indeed, the only significant difference between values in substance P-injected (L) and control (R) ears in W/WV mice was the 16% greater value for aqueous soluble counts per minute in the L ears, a finding of uncertain biological significance. Substance P-induced tissue swelling and granulocyte infiltration are associated with mast cell degranulation. The mice whose ear thickness measurements are shown in Fig. 1 , were killed at 4, 8, 24 , or 48 h after substance P injection and the substance P-injected and contralateral control ears were processed for 1 gm, Epon-embedded Giemsa-stained sections.
The sections were examined as previously described for assessment of the extent of mast cell degranulation and for quantitation of the number of granulocytes per square milliliter of dermis (37) . In WBB6F,-+/+ mice, substance P elicited an infiltrate of leukocytes which consisted predominantly (> 90%) of neutrophils with much smaller numbers of eosinophils (generally < 5% of total leukocytes). The infiltrates were detectable 4 h after injection, increased slightly by 24 h, and had resolved by 48 h (Fig. 3) . The reactions were not impres- sive, however, with total leukocyte counts in substance P-injected sites exceeding those in contralateral control ears injected with vehicle by only 5-10-fold. In W/Wv mice, 5 nmol (Fig. 3 ) or 1 nmol (data not shown) of substance P-induced amounts of leukocyte infiltration that were not significantly different from those observed at contralateral control injection sites.
Substance P induced extensive mast cell degranulation in +/+ mice, with the highest percentage of mast cells exhibiting extensive degranulation observed at the 4-h interval (91.4±1.5% or 69.7±3.4% after injection of 5 or 1 nmol/site, respectively). A reduction in the number of extensively degranulated mast cells seen at sites of substance P injection at later intervals (e.g., 49.9±6.8% or 35.6±8.3% 24 h after 5 or 1 nmol/site, respectively), probably reflected partial recovery from activation. Examination of sites of vehicle injection revealed little or no mast cell degranulation (0.6±0.3% or 1.5±1.5% extensively degranulated 4 h after 5 or 1 nmol/site, respectively), but a minor population of cells did exhibit slight alterations of cytoplasmic granule morphology (3.6±1.3% or 7.8±2.2% 4 h after 5 or 1 nmol/site, respectively), perhaps related to the trauma of injection.
To establish the relationships among doses of substance P and the extent of mast cell degranulation, tissue swelling, or leukocyte infiltration elicited, the left ears of additional WBB6F,-+/+ mice were injected with 8, 40, or 200 pmol of substance P, the swelling responses were recorded, and the mice were killed for histological analysis of the ears 4 h after injection. The data were pooled with those obtained from those WBB6F,-+/+ mice used in Fig. 3 which were killed 4 h after injection of 1 or 5 nmol (1,000 or 5,000 pmol) of substance P (Table II) .
In these experiments, substance P elicited a significant swelling response in +/+ mice when injected at 40 pmol/site, whereas significant granulocyte infiltration was first observed at 200 pmol/site. At the various doses of substance P tested there were strong correlations between the extent of mast cell degranulation elicited and the tissue swelling (r = 0.96, P < 0.02) or granulocyte infiltration (r = 0.88, P < 0.05) observed, and also between the amounts of tissue swelling and granulocyte infiltration (r = 0.96, P < 0.02). Even For clarity, the swelling reaction to substance P in each mouse was calculated as the A thickness (1 h postinjection value minus baseline value) for the substance P injected L ear minus the A thickness for the vehicle injected contralateral control (R) ear, and values are shown as mean±SEM for each dose. § Significant differences between values for L and R ears are indicated (* P < 0.05, ** P < 0.01, *** P < 0.001). 11 All mice were sacrificed at 4 h after injection for histological assessment of granulocyte infiltration and mast cell degranulation at the injection sites (see Methods).
extensively degranulated, P < 0.001), these doses elicited similar amounts of tissue swelling and granulocyte infiltration. Thus, 200 pmol of substance P was sufficient to elicit a near maximal response.
Six WCB6F1-Sl/Sld mice and six congenic normal mice were also examined 4 h after injection of 1 pmol of substance P. In +/+ mice, this dose of substance P elicited extensive degranulation of 73.2±7.6% of the mast cells at the site, compared to 0.5±0.2% for the contralateral vehicle-injected ears (P < 0.0003). The number of neutrophils in substance P or vehicle-injected +/+ ears was 55.3±9.0 vs. 4.0±1.5/mm2 ofdermis (P < 0.002); the corresponding values for substance P-or vehicle-injected ears in S/Sld mice were 2.8±1.5 vs. 3 
.0±1.3/ mm2 (NS).
W/W' mice with adoptively transferred populations ofdermal mast cells exhibit mast cell degranulation, augmented tissue swelling and vascular permeability, and granulocyte infiltration at sites ofsubstance P injection. To evaluate whether the insensitivity of W/WV mouse skin to the effects of substance P reflected this animal's mast cell deficiency, as opposed to other consequences of its mutations, we injected the neuropeptide into the mast cell-reconstituted (left) and contralateral control (mast cell-deficient) ears of W/Wv mice which had received, at least 10 wk earlier, an injection into the left ear of 0.5 x 106 culture-derived mast cells of +/+ bone marrow origin. Fig. 4 shows that 5 nmol of substance P elicited a swelling response in the mast cell-reconstituted ears that was significantly greater than that in the contralateral mast cell-deficient ears at all intervals up to 8 h after injection. Indeed, the responses in mast cell-reconstituted ears of W/Wv mice were quite similar to those elicited when the same dose ofsubstance P was injected into the ears of congenic +/+ mice (Fig. 1) . Table III shows the extent of mast cell degranulation, the swelling responses and the leukocyte infiltration elicited when various doses of substance P were injected into the mast cell- The left ears received an intradermal injection of 0.5 X 106 growth factor-dependent mast cells of +/+ bone marrow origin at least 10 wk before the experiment (see Methods). Substance P (in HMEM-PIPES) was injected into both ears, the swelling responses were assessed at various intervals thereafter, and the mice were killed for histological assessment of granulocyte infiltration, mast cell numbers, and extent of mast cell degranulation in injection sites 2 h (1,000 or 40 pmol) or 4 h (5,000 or 200 pmol) after injection. § Significant differences between values for L and R ears are indicated (* P < 0.05, ** P < 0.01, *** P < 0.001).
reconstituted and contralateral mast cell-deficient ears of W/Wl mice. As in +/+ mice, a significant swelling response was elicited in mast cell-reconstituted ears by 40 We also evaluated '251I-fibrinogen extravasation and '251-fibrin deposition in mast cell reconstituted and contralateral mast cell-deficient ears injected with 1,000 pmol of substance P (Table IV) . Significantly more total, aqueous soluble, urea soluble, and urea insoluble (cross-linked fibrin-associated) counts per minute were present in mast cell-reconstituted than in mast cell-deficient ears.
Effect ofCa2+ on the cutaneous mast cell degranulation and tissue swelling elicited by substance P. Studies of the effects of substance P on isolated rat peritoneal mast cells indicate that mast cell degranulation by substance P does not require extracellular calcium and actually is inhibited by levels of extracellular calcium in excess of 0.1 mM (43) . In addition, many previous evaluations of the effects of intradermal substance P were based on analyses of the peptide injected in Ca2+-free vehicle (4) (5) (6) (7) (8) 11) . We therefore compared the responses of WBB6F,-+/+ mice to injections of low doses of substance P solubilized either in HBSS lacking Ca2+ and Mg2" The left ears of these four mice received an intradermal injection of 0.5 x 106 growth factor-dependent mast cells of +/+ bone marrow origin at least 10 wk before the experiment (see Methods). 20 min before challenge of both ears with substance P in HMEM-PIPES, the mice received '25I-GPF (4.7 x 106 cpm i.v.). Ear swelling was measured with a micrometer at various intervals after challenge, the mice were killed at 2 h, and the ears were processed for analysis of the amount and pattern of solubility of '25I-GPF-derived cpm (see Methods). At the time of sacrifice, the '251-cpm in 50 Ml PPP = 80,847±6,408 cpm. The histological findings in these mice are included in Table III. achieve statistical significance when Ca2l was omitted (L-R = 0.1±36 or 2.4±2.5 X 10-4 inch at 1 or 2 h, respectively). This result reflected the larger control reactions in right ears injected with Ca2l-free as opposed to Ca2+-containing vehicle.
Histological analysis indicated that mast cell degranulation at sites of injection of substance P was greater when the neuropeptide was injected in medium lacking Ca2', but that control sites injected with Ca2"-free vehicle alone also exhibited more mast cell activation than did corresponding control sites injected with medium containing 1.3 mM Ca2+. For example, in the L ears of mice injected with 8 pmol substance P, the values for extensively degranulated mast cells were 2.1±0.6% (+Ca2+) vs. 16.2±4.0% (-Ca2"), P < 0.005, while the values for vehicle-injected R ears were 0.8±0.4% (+Ca2+) vs. 4 .8±1.3% (-Ca2+), P < 0.02. Little or no neutrophil infiltration occurred at sites of injection of 2, 8, or 40 pmol of substance P, whether or not the vehicle contained Ca2+ (mean values = 0. 2-9.3 granulocytes/mm2 of dermis at 4 h in substance P-injected ears, NS vs. values for contralateral vehicle-injected ears).
Assessment ofthe activity ofpeptides structurally related to substance P. Studies of rat peritoneal mast cells in vitro indicate that the basic amino acid residues in the NH2-terminal sequence of substance P are essential for its ability to cause histamine release, but that binding of substance P to the mast cells is dependent on the COOH-terminal portion ofthe molecule (8, 43, 44) . Thus, substance P1 4was substantially less active than native substance PI -II in releasing histamine from rat peritoneal mast cells, whereas the COOH-terminal heptapeptide or octapeptide (substance P4 11) was inactive in this assay system (8, 43, 44) . By contrast, substance P1.4 was inactive in doses up to 12.5 nmol/site when tested for its ability to induce alterations of vascular permeability (a wheal) in human skin, whereas substance P4_1 X had 40% of the activity of substance PI, I in this system (8) . The latter result indicates that while substance P411 is inactive as a histamine-releasing agent when tested against purified rat peritoneal mast cells in vitro, it is able to induce alterations in vascular permeability when administered to human skin in vivo.
We quantitated the effects of substance P,-or substance P411 on cutaneous mast cell degranulation, tissue swelling, and leukocyte infiltration after injection of these peptides into the skin of WBB6F,-+/+ mice. As shown in Table V 
Discussion
We found that virtually all ofthe tissue swelling, augmentation of interstitial 1251-fibrin deposition, and leukocyte infiltration that followed intradermal injection of substance P into mouse skin was mast cell-dependent. Indeed, injection of up to 5 nmol of substance P into the skin ofgenetically mast cell-deficient W/W' or Sl/Si" mice produced effects which were little or no different than those observed after injection of vehicle alone. By contrast, injection of as little as 2 pmol of substance P into +/+ mice induced significant cutaneous swelling. Thus, normal mice are at least 1,000-fold more sensitive to the vascular permeability-enhancing effects of substance P than are the congenic mast cell-deficient mice. Two lines of evidence support the conclusion that the substance P-induced tissue swelling and leukocyte infiltration observed in our study were largely mast cell-dependent. First, when various doses of substance P ,000 pmol) were tested in WBB6F,-+/+ mice, there was an excellent correlation between the extent of mast cell degranulation at the sites of in- We found that the effects of substance P on cutaneous vascular permeability occurred sooner and at lower doses of peptide than did effects on leukocyte infiltration. Moreover, the intensity of leukocyte infiltration induced by substance P was quite modest compared to that seen with other stimuli, and even this weak effect required injection of large amounts ofsubstance P. For example, the number ofneutrophils at sites of WBB6F,-+/+ skin injected 24 h previously with 5 nmol of substance P was 46±10/mm2, a value that was only -10 times that in the contralateral control ears injected with vehicle and only -1.2% ofthe value at similar sites treated epicutaneously with 10 sg phorbol 12-myristate 13-acetate (PMA) (37) . By contrast, the tissue swelling attributable to 5 nmol substance P (1 h after challenge in WBB6F,-+/+ mice) was -40% that induced by PMA (6 h after challenge, reference 37). Thus, even though the cutaneous granulocyte infiltration that follows intradermal injection of substance P, like that observed by Matsuda et al. in the tissue surrounding subcutaneous air pouches injected with the peptide (27) , was largely mast cell dependent, this represented a relatively weak effect of the peptide compared with its ability to augment vascular permeability.
Previous work indicated that substance P-induced mast cell degranulation did not require extracellular calcium and was inhibited when levels of extracellular calcium exceeded 0.1 mM (8, 43, 44 was tested, it induced augmented vascular permeability in both mast cell-deficient and congenic +/+ mice, suggesting that the ability ofthis peptide to induce a wheal in human skin (8) may be at least in part a mast cell-independent effect. However, the peptide did induce more granulocyte infiltration in +/+ than in W/WV mice, and modest but significant mast cell degranulation was detected at injection sites.
The fact that the intradermal injection of substance P411 resulted in degranulation of cutaneous mast cells when tested at doses similar to those which did not induce degranulation of rat peritoneal mast cells in vitro (8) activation of cutaneous mast cells by substance P and related peptides, whether by receptor-mediated or other mechanisms, as opposed to indirect activation of mast cells as a result of other local changes (e.g., complement activation) induced at sites of peptide injection. Such indirect mechanisms of mast cell activation may have been triggered in association with or as a result of the ability of substance P41 I to augment vascular permeability independently of the mast cell.
Similarly, the results presented here are not incompatible with evidence that important mast cell-independent effects of substance P or other neuropeptides can be observed under different circumstances. For example, Kowalski and Kaliner showed that ES can induce an apparently mast cell-independent augmentation of vascular permeability in the rat which is detectable immediately (within a few minutes) after stimulation (13) . The procedure employed in our study is not well suited for identifying neuropeptide-dependent changes induced within a few minutes of challenge, since the intradermal injection of 20 ul of fluid itself causes an increase in ear thickness during this interval. Kowalski et al. also showed that W/WV and +/+ mice exhibit indistinguishable alterations in vascular permeability in response to intravenous substance P.2 This observation is compatible with the finding that the vasodilatory effects of intraarterial substance P in human skin (26) , unlike the effects induced by intradermal administration of the peptide (4-8, 1 1), are not inhibited by antihistamines. Taken together with our results, these findings indicate that the extent to which the vascular effects of substance P are mast cell-dependent may be critically influenced by the route of administration of the peptide. For example, intravenous or intraarterial administration favors direct interactions with vascular endothelial cells, whereas intradermal injection facilitates interactions with interstitial elements such as mast cells.
In fact it should be emphasized that our experiments, like many previous reports, specifically evaluated the effects of the intradermal injection of substance P and related peptides, not the release of peptides from endogenous sources. While our results certainly are consistent with the possibility that some of the local consequences of substance P release by peptidergic nerves are mast cell dependent, they by no means prove that this is so. Identifying the extent of the mast cell's actual contributions to the local consequences of endogenous neuropeptide release in various tissues and organs represents a potentially important but difficult challenge for future work. Indeed, it should be appreciated that the reactions induced by substance P and other neuropeptides that can activate mast cells are likely to be under complex regulatory control in vivo. The effects observed in particular organs or tissues will depend on such factors as the concentration of endogenous neuropeptide that might be achieved in the immediate vicinity of its release, the proximity of mast cells to sites of neuropeptide release, the sensitivity of that particular mast cell population to activation (directly or indirectly) by neuropeptide-dependent mechanisms, and the local distribution and activity ofenzymes capable ofdegrading the neuropeptides (45, 46) . Many (perhaps all) of these factors exhibit considerable species and anatomical variation (reviewed in 8, 14-16, 46, 47) .
Nevertheless, our findings indicate that virtually all of substance P's ability to elicit cutaneous swelling and leukocyte infiltration upon intradermal injection into mouse skin is mast cell dependent. This result, taken together with evidence indicating that human cutaneous mast cells are particularly sensitive to stimulation by substance P (4, 5-8, 10-12, 15, 16), suggests that the wheal component ofthe response to intradermal injection of substance P in human skin might represent a mast cell-dependent effect of the peptide, not a direct action of substance P on the vasculature. Thus, even though antihistamines are much more effective in blocking the flare, rather than the wheal, induced by intradermal substance P (4, 8-1 1), this might simply reflect the relative importance of histamine release, as opposed to other consequences of mast cell activation, in these two components of the response (1 1, 15, 16 ).
